PDCD1 and non-small cell lung carcinoma: In 2015, the anti-programmed cell death 1 (PD-1) antibodies nivolumab and pembrolizumab were the first immune checkpoint inhibitor to be approved by the food and drug administration (FDA) for the treatment of advanced squamous and non-squamous NSCLC [1–4].